Halozyme Therapeutics, Inc.
HALO
$62.54
-$0.41-0.65%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 298.01M | 290.08M | 231.35M | 195.88M | 230.04M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 298.01M | 290.08M | 231.35M | 195.88M | 230.04M |
| Cost of Revenue | 62.50M | 67.88M | 60.65M | 47.44M | 73.63M |
| Gross Profit | 235.51M | 222.20M | 170.71M | 148.44M | 156.41M |
| SG&A Expenses | 42.25M | 41.24M | 35.71M | 35.13M | 37.61M |
| Depreciation & Amortization | 17.76M | 17.76M | 17.76M | 17.76M | 17.76M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 122.51M | 126.89M | 114.12M | 100.34M | 129.00M |
| Operating Income | 175.50M | 163.20M | 117.24M | 95.54M | 101.04M |
| Income Before Tax | 178.21M | 165.15M | 117.74M | 96.03M | 101.18M |
| Income Tax Expenses | 41.20M | 28.14M | 24.50M | 19.21M | 15.79M |
| Earnings from Continuing Operations | 137.01M | 137.01M | 93.25M | 76.82M | 85.39M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 137.01M | 137.01M | 93.25M | 76.82M | 85.39M |
| EBIT | 175.50M | 163.20M | 117.24M | 95.54M | 101.04M |
| EBITDA | 194.52M | 182.16M | 136.07M | 114.35M | 120.43M |
| EPS Basic | 1.08 | 1.08 | 0.73 | 0.61 | 0.66 |
| Normalized Basic EPS | 0.87 | 0.81 | 0.58 | 0.46 | 0.48 |
| EPS Diluted | 1.06 | 1.05 | 0.72 | 0.60 | 0.65 |
| Normalized Diluted EPS | 0.85 | 0.79 | 0.57 | 0.45 | 0.47 |
| Average Basic Shares Outstanding | 126.41M | 126.85M | 127.12M | 126.94M | 129.05M |
| Average Diluted Shares Outstanding | 128.98M | 130.13M | 129.22M | 128.89M | 131.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
